Journal History
| 2009 | The inaugural issue was released. Cancers was published as a quarterly journal. |
| 2013 | Cancers was indexed in PubMed (NLM) and Scopus. |
| 2015 | Cancers changed to publish in article number order instead of in page range order. |
| 2016 | Cancers adopted a monthly publication schedule. Cancers announced the first edition of the Travel Awards. The journal Twitter account was established. |
| 2017 | Cancers was indexed in Science Citation Index Expanded (SCIE) - Web of Science (Clarivate Analytics). |
| 2018 | Cancers received a first Impact Factor of 5.326. The journal ranked 44/222 (Q1) in the 'Oncology' category. |
| 2019 | Cancers received an Impact Factor of 6.162. The journal ranked 31/229 (Q1) in the 'Oncology' category in JCR. Cancers published more than 2000 papers in the year of 2019. Cancers became an affiliated journal of the Signal Transduction Society (STS). |
| 2020 | Cancers established the following sections: - Molecular Cancer Biology; - Cancer Immunology and Immunotherapy; - Cancer Biomarkers; - Cancer Epidemiology and Prevention; - Cancer Pathophysiology; - Tumor Microenvironment; - Cancer Causes, Screening and Diagnosis; - Cancer Nursing and Care; - Cancer Therapy; - Clinical Trials of Cancer; - Systematic Review or Meta-Analysis in Cancer Research; - Methods and Technologies Development; - Cancer Informatics and Big Data. Cancers announced the first edition of the Outstanding Reviewer Awards and second edition of the Young Investigator Awards. |
| 2021 | Cancers adopted a semi-monthly publication schedule. Cancers received an Impact Factor of 6.639. The journal ranked 51/242 (Q1) in the 'Oncology' category. Cancers established the following sections: - Pediatric Oncology; - Infectious Agents and Cancer. |
| 2022 | Section Cancer Nursing and Care has been renamed as Section Transplant Oncology and Cancer Nursing Care. Cancers has received an Impact Factor of 6.575, ranked 60/245 (Q1) in the 'Oncology' category. Cancers has established the following section: - Cancer Drug Development; - Cancer Metastasis. |
Editor-in-Chief
| 2009–2015 | Editor-in-Chief: Prof. Dr. Robert H. Weiss |
| 2015–present | Editor-in-Chief: Prof. Dr. Samuel C. Mok |
Section Editor-in-Chief
| 2020–2022 | Section Editor-in-Chief: Prof. Dr. Eduardo Nagore for the section on Cancer Epidemiology and Prevention |
| 2020–present | Section Editor-in-Chief: Dr. Carlos S. Moreno for the section on Cancer Biomarkers Section Editor-in-Chief: Prof. Dr. Donat Kögel for the section on Molecular Cancer Biology Section Editor-in-Chief: Dr. Barbara Wegiel for the section on Cancer Immunology and Immunotherapy Section Editor-in-Chief: Dr. Nicola Amodio for the section on Cancer Pathophysiology Section Editor-in-Chief: Prof. Dr. Sanjay Gupta for the section on Tumor Microenvironment Section Editor-in-Chief: Dr. Kevin Camphausen for the section on Cancer Therapy Section Editor-in-Chief: Prof. Dr. Alexandre Escargueil for the section on Cancer Therapy Section Editor-in-Chief: Prof. Dr. Massimo Di Maio for the section on Systematic Review or Meta-Analysis in Cancer Research Section Editor-in-Chief: Prof. Dr. Fiona Lyng for the section on Methods and Technologies Development Section Editor-in-Chief: Dr. Jason Roszik for the section on Cancer Informatics and Big Data Section Editor-in-Chief: Prof. Dr. Massoud Mirshahi for the section on Cancer Causes, Screening and Diagnosis |
| 2021–2022 | Section Editor-in-Chief: Prof. Dr. Antoine Italiano for the section on Clinical Trials of Cancer |
| 2022–present | Section Editor-in-Chief: Dr. Maen Abdelrahim for the section on Cancer Nursing and Care Section Editor-in-Chief: Dr. Sam Mbulaiteye for the section on Infectious Agents and Cancer Section Editor-in-Chief: Prof. Dr. Anupam Bishayee for the section on Cancer Drug Development Section Editor-in-Chief: Prof. Dr. Sanjay K. Srivastava for the section on Cancer Metastasis |
